Vancouver, British Columbia – TheNewswire - March 19, 2026 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF), (the “Company” or “MindBio”), a biotechnology company commercializing AI-driven voice analytics for drug and alcohol intoxication detection announces today that it is upsizing its non-brokered private placement (the “Offering”) previously announced on February 18, 2026 from $650,000 to up to $1,500,000, pursuant to which the Company intends to now issue up to 2,500,000 units ...